Beta Bionics, Inc. Common Stock (BBNX) is a publicly traded Healthcare sector company. As of November 3, 2026, BBNX trades at $15.93 with a market cap of $910.65M and a P/E ratio of 0.00. BBNX moved -0.25% today. Year to date, BBNX is -45.69%; over the trailing twelve months it is -41.64%. Its 52-week range spans $8.80 to $32.71. Analyst consensus is buy with an average price target of $24.83. Rallies surfaces BBNX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Beta Bionics raises 2026 revenue guidance to $124 million-$126 million: Beta Bionics raised its 2026 revenue guidance to $124 million-$126 million from $121 million-$126 million. Q3 sales rose 30% to $35.51 million, while net loss widened 71% to $24.35 million and adjusted EBITDA loss missed estimates.
| Metric | Value |
|---|---|
| Price | $15.93 |
| Market Cap | $910.65M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $32.71 |
| 52-Week Low | $8.80 |
| Volume | 18.45K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
13 analysts cover BBNX: 0 strong buy, 9 buy, 4 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $24.83.